

MedStar Health

# Advances in Urologic Oncology 2024

**November 1 to 2, 2024**

Bethesda Marriott • Bethesda, MD



## Course Directors:

### **MICHAEL B. ATKINS, MD**

Georgetown University Medical Center  
MedStar Georgetown University Hospital  
Washington, D.C.

### **KEITH J. KOWALCZYK, MD**

MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Georgetown University School of Medicine  
Washington, D.C.

## Course Co-Directors:

### **MICHAEL A. CARRASQUILLA, MD**

MedStar Georgetown University Hospital  
Washington, D.C.

### **MOHIT GUPTA, MD**

MedStar Georgetown University Hospital  
Georgetown University School of Medicine  
Washington, D.C.

### **ROSS E. KRASNOW, MD, MPH**

MedStar Washington Hospital Center  
Washington, D.C.

### **LAMBROS STAMATAKIS, MD**

MedStar Washington Hospital Center  
Washington, D.C.



MedStar Health

# Continuing Education Credit Information

## Course Description

The *MedStar Health Advances in Urologic Oncology 2024* conference is a comprehensive educational event designed for healthcare professionals involved in the diagnosis, treatment, and management of urologic cancers. This conference will cover the latest advancements in the field, focusing on prostate, bladder, kidney, testicular, and testicular cancers. Attendees will gain in-depth knowledge of cutting-edge research, emerging therapies, and innovative treatment approaches through a series of lectures, panel discussions, and keynote presentations from leading experts.

**Prostate Cancer:** The prostate cancer sessions will provide an in-depth look at the latest advancements in the diagnosis, treatment, and management of this prevalent disease. Discussions will include advanced imaging techniques, such as PSMA PET imaging and multiparametric MRI, which have revolutionized the detection and staging of prostate cancer. Emerging techniques in transperineal biopsy will be highlighted for their benefits in reducing infection risks and improving diagnostic accuracy. Genomic testing is increasingly crucial in guiding treatment decisions, and the conference will explore the evolving role of genomic classifiers like Decipher, particularly in identifying candidates for active surveillance and tailoring treatment plans based on individual genetic profiles. Additionally, the latest advancements in systemic therapy, including androgen receptor inhibitors and chemotherapy, will be examined for their effectiveness in treating advanced and metastatic prostate cancer. Key trials such as ENZAMET, TITAN, and ARCHES will be discussed to highlight the benefits of novel hormonal agents in improving survival outcomes. Strategies for managing castration-resistant prostate cancer (CRPC) will be discussed, focusing on new agents such as lutetium Lu 177 vipivotide and their role in targeting metastatic disease. The VISION trial will be reviewed for its significant findings on the efficacy of PSMA-targeted radioligand therapy in CRPC. A dedicated session on the management of active surveillance patients will explore best practices for monitoring and decision-making, ensuring that patients receive the most appropriate care based on their individual risk profiles and disease progression. This will include a discussion of the ProtecT trial outcomes, which demonstrated the safety and efficacy of active surveillance in low-risk prostate cancer, and the role of MRI and genomic testing in surveillance protocols.

**Kidney Cancer:** Kidney cancer, particularly renal cell carcinoma (RCC), presents significant challenges in both diagnosis and treatment. The conference will delve into the evolving guidelines on partial versus radical nephrectomy and the role of cytoreductive nephrectomy in the treatment landscape. Recent advancements in systemic therapies, including immune checkpoint inhibitors and targeted therapies, will be highlighted, with a focus on key clinical trials such as CheckMate 214, which established the combination of nivolumab and ipilimumab as a first-line treatment for advanced RCC, and KEYNOTE-426, which showed the benefits of pembrolizumab plus axitinib. Comprehensive strategies for managing metastatic RCC will be discussed, including the use of combination therapies and the latest research on biomarkers for treatment selection. The conference will review the PROBE trial, which is investigating the role of cytoreductive nephrectomy in the context of immune checkpoint-based combination therapies. Attendees will gain insights into the latest advances in adjuvant therapy, with a review of the KEYNOTE-564 trial demonstrating the efficacy of pembrolizumab in the adjuvant setting for high-risk RCC patients.

**Bladder Cancer:** Bladder cancer management has seen significant advancements with the introduction of novel intravesical therapies and systemic treatments. The conference will provide clarity on treatment strategies for non-muscle invasive bladder cancer (NMIBC), including alternatives for BCG-naïve and BCG-resistant disease. Emerging therapies for advanced bladder cancer will be discussed, along with the role of blue light cystoscopy in enhancing cancer detection and management. Updates on the use of immune checkpoint inhibitors and combination therapies for metastatic bladder cancer will be provided, with a focus on key trials such as IMvigor130, which evaluated atezolizumab in combination with chemotherapy, and the DANUBE trial, which assessed durvalumab with or without tremelimumab. Comprehensive strategies for managing advanced bladder cancer will be explored, including real-world applications of new treatments and their impact on patient outcomes.

**Testicular Cancer:** Penile and testicular cancers, though less common, require specialized diagnostic and treatment approaches. The conference will highlight advances in diagnostic techniques, including the role of miRNA profiling and other biomarkers in early detection. Emerging systemic treatment options for metastatic and advanced testicular cancer will be covered, with an emphasis on the role of platinum-based chemotherapy and novel targeted therapies. The conference will review key clinical trials and provide comprehensive strategies for managing advanced penile and testicular cancers, incorporating the latest data on novel therapies and their efficacy.

**Multidisciplinary Care:** The integration of multidisciplinary care is essential for optimizing patient outcomes in urologic oncology. The conference will explore best practices for integrating care across specialties, ensuring a collaborative approach to patient management. Strategies to address and mitigate disparities in urologic oncology, focusing on the social determinants of health, will also be discussed.

## Learning Objectives

- Prostate Cancer Diagnosis and Imaging: Describe the role of advanced imaging techniques in diagnosing prostate cancer, including applying PSMA imaging and TP biopsy methods.
- Genetic and Biomarker Considerations: Evaluate the current and emerging genetic and biomarker tools for assessing prostate cancer risk and their implications for personalized treatment plans.
- Localized Prostate Cancer Treatment Options: Compare the efficacy and suitability of focal therapy, surgical options, and radiation in the treatment of localized prostate cancer.
- Management of Metastatic Prostate Cancer: Discuss the latest approaches in the systemic treatment of metastatic prostate cancer, including novel pharmacologic therapies and management strategies.
- Complex Case Discussion: Analyze the management strategies for conventional imaging negative, PSMA-positive prostate cancer patients through expert panel discussions.
- Kidney Cancer Management: Identify the latest diagnostic techniques and their impact on surgical and systemic treatment strategies for renal cell carcinoma.
- Role of Adjuvant Therapy in Kidney Cancer: Discuss the implications of recent clinical trials (e.g., KEYNOTE) on using adjuvant therapy in renal cell carcinoma.
- Bladder Cancer Therapeutics: Assess treatment strategies for high-grade non-muscle invasive bladder cancer (HG NMIBC), including alternatives to BCG and management of BCG-resistant disease.
- Innovations in Testicular Cancer: Explore recent advances in diagnostics, including miRNA, and evaluate the role of surgical interventions such as RPLND and managing testicular cancer.
- Interdisciplinary Approach in Urologic Oncology: Integrate interdisciplinary approaches and collaborative strategies in treating urologic cancers, enhancing patient-centered care across various disease states.
- Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with urologic malignancies.

## Target Audience

This conference is intended for physicians, residents and fellows, physician assistants, nurse practitioners, nurses, allied health professionals, medical oncologists, oncologists, pathologists, radiation oncologists, radiologists, surgeons, urologists, and other members of the healthcare team interested in the management of prostate, kidney, bladder, and testicular cancers.

To register, please visit [MedStarHealth.org/AdvancesInUrologicOncology](https://www.MedStarHealth.org/AdvancesInUrologicOncology)

# Continuing Education Credit Information

## Accreditation



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## Credit Designation



IPCE CREDIT™

This activity was planned by and for the healthcare team and learners will receive **12.75** Interprofessional Continuing Education (IPCE) credits for learning and change.

**Physicians:** MedStar Health designates this live activity for a maximum of **12.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **12.75** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME to grant ABIM MOC credit.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

**MOC Participation Threshold:** Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

**Nurses:** This activity is approved for **12.75** ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

## Additional Information

**Attention Physician Learners:** To ensure accurate reporting of your CME credit data, to ACCME and relevant licensing boards, please verify that your CloudCME profile contains the details listed below. To access your CloudCME profile, once signed in, click My CE > Profile.

- Full name
- State of licensure
- State license number
- Birth month and day (year not required)
- National Provider Identifier (NPI)

In addition, please remember to check the box at the bottom of the CloudCME Profile page, granting the CPE department permission to report your credit data to ACCME and relevant licensing boards.

**Questions?** Email [medstarceapplications@email.sitel.org](mailto:medstarceapplications@email.sitel.org)

**CloudCME Link:** <https://medstar.cloud-cme.com>

# Course Directors

## **Michael B. Atkins, MD**

Deputy Director, Georgetown Lombardi  
Comprehensive Cancer Center  
William M. Scholl Professor and Vice-Chair  
Department of Oncology  
Georgetown University Medical Center  
Co-Director, Melanoma Center  
MedStar Georgetown University Hospital  
Washington, D.C.

## **Keith J. Kowalczyk, MD**

Physician Executive Director  
MedStar Health Urology  
Chair, Urology  
Chair, MedStar Robotic Surgery Service Line  
MedStar Georgetown University Hospital  
Georgetown University Medical Center  
Washington, D.C.

# Course Co-Directors

## **Michael A. Carrasquilla, MD**

Director, Radiation Oncology Prostate  
Cancer Program  
Radiation Oncologist  
MedStar Georgetown University Hospital  
Washington, D.C.

## **Mohit Gupta, MD**

Urologic Oncologist  
MedStar Georgetown University Hospital  
Associate Professor, Urology  
Georgetown University School of Medicine  
Washington, D.C.

## **Ross E. Krasnow, MD, MPH**

Staff Physician, Urologic Oncologist  
MedStar Washington Hospital Center  
Washington, D.C.

## **Lambros Stamatakis, MD**

Director, Urologic Oncology  
MedStar Washington Hospital Center  
Associate Professor, Urology  
Georgetown University School of Medicine  
Washington, D.C.

# Faculty

## **Sigrid V. Carlsson, MD, PhD, MPH**

Assistant Attending Epidemiologist  
Memorial Sloan Kettering Cancer Center  
Director, Clinical Research  
Josie Robertson Surgery Center  
New York, NY

## **Kimberly M. Davis, PhD**

Psychologist  
MedStar Georgetown University Hospital  
Research Assistant Professor, Oncology  
Georgetown University School of Medicine  
Washington, D.C.

## **Filipe La Fuente De Carvalho, MD, PhD**

Urologic Oncologist  
Brigham and Women's Hospital  
Assistant Professor, Surgery  
Harvard Medical School  
Boston, MA

## **Jillian Egan Kelly, MD**

Surgeon, Urologic Oncology  
Albany Med Health System  
Assistant Professor, Urology  
Albany Medical College  
Albany, NY

## **Natasha Gupta, MD, MSc**

Research Assistant Professor, Urology and  
Population Health  
NYU Langone Health  
Attending Urologist  
Manhattan VA Medical Center  
New York, NY

To register, please visit [MedStarHealth.org/AdvancesInUrologicOncology](https://www.MedStarHealth.org/AdvancesInUrologicOncology)

# Faculty

## **Hans Hammers, MD, PhD**

Professor, Internal Medicine  
Eugene P. Frenkel, M.D. Scholar in  
Clinical Medicine  
The University of Texas Southwestern  
Medical Center  
Dallas, Texas

## **Jim C. Hu, MD, MPH**

Attending Urologist  
New York-Presbyterian Hospital  
Ronald P. Lynch Professor, Urologic Oncology  
Professor, Urology  
Weill Cornell Medical College  
Cornell University  
New York, NY

## **Fatima Karzai, MD**

Deputy Clinical Director  
National Cancer Institute  
Senior Clinician  
Genitourinary Malignancies Branch  
National Institutes of Health  
Bethesda, MD

## **Pranay Krishnan, MD**

Vice Chair of Operations, Quality, and Safety  
MedStar Georgetown University Hospital  
Professor, Radiology  
Georgetown University School of Medicine  
Washington, D.C.

## **Paul D. Leger, MD, MPH**

Medical Oncologist  
MedStar Georgetown University Hospital  
Washington, D.C.

## **Charlene Mantia, MD**

Medical Oncologist  
Lank Center for Genitourinary Oncology  
Dana-Farber Cancer Institute  
Instructor, Medicine  
Harvard Medical School  
Boston, MA

## **Phillip M. Pierorazio, MD**

Chief, Section of Urology  
Penn Presbyterian Medical Center  
Professor, Surgery in Urology  
University of Pennsylvania  
Philadelphia, PA

## **Wade J. Sexton, MD**

Senior Member, Urologic Oncologist  
Department of Genitourinary Oncology  
Chief Medical Officer, Vice President of  
Medical Affairs  
Moffitt Cancer Center  
Tampa, FL

## **Paul R. Shin, MD**

Director, Reproductive Urology  
Shady Grove Fertility  
Rockville, MD

## **Hong Truong, MD**

Urologist, Urologic Oncology  
Penn State Health Milton S. Hershey  
Medical Center  
Assistant Professor, Urology  
Penn State College of Medicine  
Hershey, PA

## **Randy Vince Jr., MD, M.S.**

Director, Minority Men's Health Cutler  
Center for Men  
University Hospitals  
Assistant Professor, Urologic Oncology  
Case Western Reserve University  
Cleveland, OH

## **Heidi E. Zeich, MS, MBA**

Associate Dean of Students  
The Catholic University of America  
Washington, D.C.

# Agenda | FRIDAY

7:30 a.m. **Breakfast, Registration, and Visit the Exhibits**

8:30 a.m. **Welcome and Opening Remarks**  
Keith J. Kowalczyk, MD

## SESSION I | Prostate Cancer

Moderator: Michael A. Carrasquilla, MD

8:45 a.m. **Diet and Lifestyle Modification for Prostate Cancer**  
Natasha Gupta, MD, MSc

9:05 a.m. **Advanced Diagnostic Imaging Techniques**  
Pranay Krishnan, MD

9:25 a.m. **Transperineal (TP) vs Transrectal (TR) Biopsy**  
Jim C. Hu, MD, MPH

9:45 a.m. **Is GG1 PCa Cancer?**  
Sigrid V. Carlsson, MD, PhD, MPH

10:05 a.m. **Morning Break and Visit the Exhibits**

10:25 a.m. **Active Surveillance in Prostate Cancer**  
Sigrid V. Carlsson, MD, PhD, MPH

10:45 a.m. **Focal Therapy**  
Jim C. Hu, MD, MPH

11:05 a.m. **Surgical Advances**  
Keith J. Kowalczyk, MD

11:25 a.m. **Radiation Therapy**  
Michael A. Carrasquilla, MD

11:45 p.m. **Lunch Break and Visit the Exhibits**

12:05 p.m. **Lunch Symposium**

12:45 p.m. **Dessert Break and Visit the Exhibits**

1:00 p.m. **KEYNOTE ADDRESS**  
**Improving Equity in Prostate Cancer Outcomes**  
Randy Vince Jr., MD, M.S.

1:45 p.m. **Role of Post-Radical Prostatectomy (RP) Salvage Radiation Therapy**  
Keith J. Kowalczyk, MD

2:05 p.m. **Contemporary Management of De-Novo Castrate Sensitive Metastatic Disease and Castration-Resistant Prostate Cancer (CRPC)**  
Fatima Karzai, MD

2:25 p.m. **Prostate-Specific Membrane Antigen (PSMA): Targeted Therapy and Imaging**  
Paul D. Leger, MD, MPH

2:45 p.m. **Afternoon Break and Visit the Exhibits**

## SESSION III | Kidney Cancer

Moderator: Mohit Gupta, MD

3:00 p.m. **Contemporary Imaging in Renal Cell Carcinoma (RCC)**  
Pranay Krishnan, MD

3:20 p.m. **Active Surveillance for RCC - Biology vs. Size**  
Phillip M. Pierorazio, MD

3:40 p.m. **Role of Surgical Management in Localized and Advanced RCC**  
Mohit Gupta, MD

4:00 p.m. **Systemic Treatments for Advanced/Metastatic Disease and Role of Biomarkers**  
Michael B. Atkins, MD

4:20 p.m. **Role of Adjuvant Therapy in the Post Neoadjuvant**  
Hans Hammers, MD, PhD

4:40 p.m. **Kidney Cancer Panel Discussion**  
Moderators: Michael B. Atkins, MD; Mohit Gupta, MD  
Panelists: H. Hammers, P. Krishnan, P. Pierorazio

4:55 p.m. **Closing Remarks**

5:00 p.m. **Networking Reception with Exhibitors**

# Agenda | SATURDAY

7:30 a.m. **Breakfast, Registration, and Visit the Exhibits**

8:25 a.m. **Welcome to Day Two Opening Remarks**  
Michael B. Atkins, MD

## SESSION III | Bladder Cancer Moderator: Lambros Stamatakis, MD

8:30 a.m. **Blue Light Cystoscopy for Enhanced Detection: Pros and Cons**  
Mohit Gupta, MD

8:50 a.m. **Bacillus Calmette-Guerin (BCG) Naive High-Grade Non-Muscle-Invasive Bladder Cancer**  
Lambros Stamatakis, MD

9:10 a.m. **Emerging Therapies for BCG Resistant Disease**  
Filipe La Fuente De Carvalho, MD, PhD

9:30 a.m. **Trimodal Therapy**  
Jillian Egan Kelly, MD

9:50 a.m. **Advances in Neoadjuvant and Adjuvant Systemic Therapies**  
Charlene Mantia, MD

10:10 a.m. **Panel Discussion: How Should We Treat Patients with Clinical Complete Response to Neoadjuvant Therapy?**  
Moderator: Lambros Stamatakis, MD  
Panelists: F. De Carvalho, J. Egan Kelly, M. Gupta, C. Mantia

10:25 a.m. **Morning Break and Visit the Exhibits**

## SESSION IV | Testicular Cancer Moderator: Ross E. Krasnow, MD, MPH

10:45 a.m. **Advances in Diagnostics: Role of microRNA and Germline Testing**  
Hong Truong, MD

11:05 a.m. **Role of Retroperitoneal Lymph Node Dissection (RPLND) in Early-Stage Seminoma**  
Wade J. Sexton, MD

11:25 a.m. **Debate: Point-Counterpoint: Robotic vs. Open Retroperitoneal Lymph Node Dissection(RPLND)**  
Robotic: Ross E. Krasnow, MD  
Open: Wade J. Sexton, MD

11:45 a.m. **Systemic Therapy for Testis Cancer**  
Jennifer King, MD

12:05 p.m. **Oncofertility in Testicular Cancer**  
Paul R. Shin, MD

12:25 p.m. **Lunch Break and Visit the Exhibits**

## SESSION V | Survivorship Moderator: Keith J. Kowalczyk, MD

1:10 p.m. **Survivorship and Quality of Life in Urologic Oncology**  
Phillip M. Pierorazio, MD

1:30 p.m. **Psychosocial Aspects of Cancer Care**  
Kimberly M. Davis, PhD

1:50 p.m. **Patient Perspectives**  
Heidi E. Zeich, MS, MBA

2:10 p.m. **Panel Discussion: Integrating Survivorship into Clinical Practice**  
Moderator: Keith J. Kowalczyk, MD  
Panelists: K. Davis, P. Pierorazio, H. Zeich

2:30 p.m. **Closing Remarks**  
Keith J. Kowalczyk, MD

2:35 p.m. **Adjourn**



# Registration Information

REGISTRATION TYPE	NOW THROUGH SEPTEMBER 9	SEPTEMBER 10 TO NOVEMBER 2
Physician	\$125	\$150
Resident or Fellow	COMPLIMENTARY	COMPLIMENTARY
Physician Assistant	\$50	\$75
Nurse Practitioner	\$50	\$75
Nurse	\$50	\$75
Allied Health Professional	\$50	\$75
Medical Student	COMPLIMENTARY	COMPLIMENTARY
Industry Professional	\$200	\$225
One-Day Pass	\$75	\$90

## Online Registration Preferred

Please visit [MedstarHealth.org/AdvancesInUrologicOncology](https://www.medstarhealth.org/AdvancesInUrologicOncology) for updated program and registration information. We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at [MedStarCPE@MedStar.net](mailto:MedStarCPE@MedStar.net) or (833) 731-1273.

## Cancellation Policy

Cancellations made in writing by October 4, 2024, will be subject to a 50% penalty. No refunds will be given after October 4, 2024. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

## Venue Information

### Bethesda Marriott

5151 Pooks Hill Road | Bethesda, MD 20814  
(301) 897-9400



For grant information please contact Ada Guo at [ada.guo@medstar.net](mailto:ada.guo@medstar.net)  
For exhibit information please contact Elizabeth Romano at [elizabeth.s.romano@medstar.net](mailto:elizabeth.s.romano@medstar.net)